Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

I. Rini, Brian; Halabi, Susan; E. Rosenberg, Jonathan; M. Stadler, Walter; A. Vaena, Daniel; Ou, San-San; Archer, Laura; N. Atkins, James; Picus, Joel; Czaykowski, Piotr; P. Dutcher, Janice; J. Small, Eric

doi:10.1200/jco.2008.16.9847

Public

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

Published in Journal of Clinical Oncology • Oct 21, 2008

Authors:

Brian I. Rini

Susan Halabi

Jonathan E. Rosenberg

Abstract

PURPOSE: Bevacizumab is an antibody that binds to vascular endothelial growth factor (VEGF) and has activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN) is a historic standard first-line treatment for RCC. A prospective, randomized phase III trial of bevacizumab plus IFN versus I...

Subject

Medicine

Bevacizumab

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!